Clinical Trial

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

Investigator
Complete title:
Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)
Trial phase:
Phase II
Study ID:
NCT01812252
Local study ID:
2661.00
Summary:
This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells, and may prevent the myelodysplastic syndrome from coming back after the transplant. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Trial keywords:
Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
Seattle Cancer Care Alliance Intake Office
phone 1-800-606-7800
Toll-free